Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Bruker Corporation is a medical devices business based in the US. Bruker Corporation shares (BRKR) are listed on the NASDAQ and all prices are listed in US Dollars. Bruker Corporation employs 7,765 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $62.95 |
|---|---|
| 52-week range | $55.76 - $92.17 |
| 50-day moving average | $60.71 |
| 200-day moving average | $71.42 |
| Wall St. target price | $77.63 |
| PE ratio | 35.0595 |
| Dividend yield | $0.17 (0.31%) |
| Earnings per share (TTM) | $1.85 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $62.95 from 2022-06-29
| 1 week (2022-06-24) | -1.92% |
|---|---|
| 1 month (2022-05-28) | N/A |
| 3 months (2022-03-28) | N/A |
| 6 months (2021-12-31) | -24.98% |
| 1 year (2021-07-01) | -17.73% |
|---|---|
| 2 years (2020-07-01) | 55.09% |
| 3 years (2019-07-01) | 24.90% |
| 5 years (2017-06-30) | 118.27% |
Valuing Bruker Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bruker Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bruker Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 35x. In other words, Bruker Corporation shares trade at around 35x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Bruker Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.64. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bruker Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Bruker Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $524.6 million.
The EBITDA is a measure of a Bruker Corporation's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $2.5 billion |
|---|---|
| Operating margin TTM | 17.74% |
| Gross profit TTM | $1.2 billion |
| Return on assets TTM | 8.28% |
| Return on equity TTM | 28.21% |
| Profit margin | 11.47% |
| Book value | $6.81 |
| Market capitalisation | $9.7 billion |
TTM: trailing 12 months
Dividend payout ratio: 8.87% of net profits
Recently Bruker Corporation has paid out, on average, around 8.87% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.31% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Bruker Corporation shareholders could enjoy a 0.31% return on their shares, in the form of dividend payments. In Bruker Corporation's case, that would currently equate to about $0.17 per share.
While Bruker Corporation's payout ratio might seem low, this can signify that Bruker Corporation is investing more in its future growth.
Bruker Corporation's most recent dividend payout was on 16 June 2022. The latest dividend was paid out to all shareholders who bought their shares by 30 May 2022 (the "ex-dividend date").
Over the last 12 months, Bruker Corporation's shares have ranged in value from as little as $55.7553 up to $92.1673. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Bruker Corporation's is 1.25. This would suggest that Bruker Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.